USPTO serial 87481048
NOVEOS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 30, 2021
- Examiner
- FRENCH, CURTIS W
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with NOVEOS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $2,144*
Plus Government fees of $1,950
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Garden Grove, CA, US
Garden Grove, CA, US
Garden Grove, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Gregory B. Coy
Gregory B. Coy TAFT STETTINIUS & HOLLISTER LLPONE INDIANA SQUARE, SUITE 3500INDIANAPOLIS, IN 46204UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Diagnostic reagents and preparations for scientific, clinical laboratory, medical laboratory, reference laboratory, hospital laboratory, physician office laboratory, companion diagnostic or research use; control and calibrating fluids and reagents for medical diagnostic instruments; control and calibrating fluids and reagents for laboratory instruments used for in vitro diagnostic testing and/or analysis; diagnostic reagents for scientific or medical research use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; reagents for use in scientific apparatus for chemical or biological analysis; laboratory chemicals, namely, an antibody reagent used for the detection of antigens for in vitro diagnostic use; diagnostic test kits comprised of monoclonal antibodies, antigens, buffers, assay components and reagents for scientific or medical laboratory use; assays for research purposes; assay kits consisting primarily of assays, pre-mixes and onboard mixes for scientific, clinical laboratory, reference laboratory, hospital laboratory, physician office laboratory, companion diagnostic or research purposes | ACTIVE | Jan 14, 2021 |
| 005 | Medical diagnostic reagents; biological reagents and chemical preparations and reagents for medical purposes; medical diagnostic assays for testing of bodily fluids in the detection, monitoring, and/or prediction of disease or other conditions, disease states and/or clinical response; containers and kits containing medical diagnostic reagents for use in blood analyzers and analyzers for measuring, testing and analyzing body fluids; diagnostic preparations for medical purposes; diagnostic test kits comprised of medical diagnostic reagents and assays for testing in the field of medical diagnostics; diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; autoimmune diagnostic test kits consisting primarily of reagents, buffer concentrates, calibrators, controls, substrates, diluents, capture reagents, mixes of capture reagents, antibodies and conjugates for medical use for testing presence of autoimmune disease and allergic hypersensitivity; Quantitative Specific Immunoglobulin E (IgE) test kits consisting primarily of antibodies, capture reagents, mixes of capture reagents, calibrators, calibration verification samples, controls and reagents for testing presence of allergic hypersensitivity and allergy disease; diagnostic reagents for medical use; assay kits consisting primarily of assays for medical use for testing presence of allergic hypersensitivity and allergy disease | ACTIVE | Jan 14, 2021 |
| 009 | Research and commercial laboratory analyzers for measuring, testing and analyzing blood and other bodily fluids; scientific instruments, namely, electronic analyzers for testing and analyzing chemical and biological substances for the presence, absence, or level of autoimmune disease or allergic hypersensitivity; laboratory instruments for in vitro diagnostic testing and/or analysis; laboratory equipment for use in the field of medical diagnostics, namely, laboratory test and collection kits comprised of magnetic microparticles, ready-to-use immunochemistry reagents and stock fluids for in vitro diagnostic testing of blood or other body fluid to detect the presence of autoimmune disease, allergic hypersensitivity or allergy disease; calibration devices for calibrating blood analyzers; analyzers for measuring, testing and analyzing body fluids; laboratory instruments for allergic hypersensitivity, allergy disease and autoimmune disease diagnostics and identification; reagents and consumables for use in research and commercial laboratory blood analyzers and research and commercial laboratory analyzers for measuring, testing and analyzing body fluids; laboratory apparatus, namely, a diagnostic instrument utilizing microparticle-based solid phase and chemiluminescent/fluorescent detection together with related reagents for medical use; computer operating software, firmware and hardware for medical diagnostic instruments; computer operating software, firmware and hardware for immunoassay analyzers for blood and other bodily fluid testing; computer software, firmware and hardware for configuring, supporting, monitoring and/or troubleshooting medical diagnostic instruments; computer software, firmware and hardware for configuring, supporting, monitoring and/or troubleshooting immunoassay analyzers for blood and/or bodily fluid testing; electronic data interface for medical diagnostic instruments; electronic data interface for immunoassay analyzers and blood and/or bodily fluid testing systems; computer software, firmware and hardware for managing interface between medical diagnostic instruments, laboratories and other systems; computer software, firmware and hardware for managing interface between laboratory instruments, laboratories and other systems; computer software, firmware and hardware for processing diagnostic laboratory data; computer software, firmware and hardware for use in medical diagnostic testing; computer software, firmware and hardware for analyzing allergic and autoimmune diseases; electronic publications, namely, instruction sheets and manuals for in vitro diagnostic instruments, laboratory automation systems recorded on computer-readable media, and related software | ACTIVE | Jan 14, 2021 |
| 010 | Immunoassay analyzers for medical diagnostic use; medical diagnostic instruments for in vitro diagnostic testing and/or analysis; medical diagnostic instruments for the analysis of body fluids; equipment for testing bodily fluids for medical diagnosis; medical diagnostic analyzers for measuring, testing and analyzing blood or other body fluids; diagnostic apparatus, namely, automated enzyme immunoassay analyzer for allergic hypersensitivity and allergy disease, autoimmune disease diagnostic testing and companion diagnostic testing; medical immunoassays, diagnostic tests and kits used in blood or other body fluid testing for allergic hypersensitivity and allergy disease, autoimmune disease diagnostic testing and companion diagnostic testing comprised of magnetic microparticles, ready-to-use immunochemistry reagents and stock fluids; medical apparatus, namely, allergen kits for testing presence of allergic hypersensitivity and allergy disease comprised of magnetic microparticles, ready-to-use immunochemistry reagents and stock fluids for in vitro diagnostic testing of blood or other body fluid to detect the presence of allergic hypersensitivity or allergy disease; medical disposable cups, cuvettes, probe tips and tubes | ACTIVE | Jan 14, 2021 |
| 037 | Maintenance and repair of medical diagnostic equipment; providing remote electronic troubleshooting services in the nature of maintenance and repair of medical diagnostic equipment for laboratories; providing installation, maintenance and repair services for medical diagnostic instruments; maintenance of computer hardware for blood and other body fluid testing instruments and system | ACTIVE | Jan 14, 2021 |
| 042 | Providing an online computer database featuring non-downloadable operating manuals and other information for in vitro diagnostic laboratory instruments and related software; providing technical support services for in vitro diagnostic laboratory instruments and systems, namely, troubleshooting in the nature of diagnosing problems with in vitro diagnostic laboratory instruments and associated software, firmware and hardware; providing monitoring services for in vitro diagnostic laboratory equipment to evaluate proper functioning; remote monitoring of medical diagnostic laboratory systems to evaluate proper functioning; providing temporary use of web-based software for management, tracking, reporting, sharing, monitoring and analysis of data pertaining to blood and other bodily fluid testing instruments and systems and pertaining to performance or errors associated with the instruments and systems and for managing data associated with the instruments and systems; hosting, managing, developing, and maintaining applications, software, and web sites related to medical diagnostics instruments and systems; hosting an on-line network environment for users to share data in the field of medical diagnostics; maintenance and updates of computer software and firmware for blood and other body fluid testing instruments and systems | ACTIVE | Jan 14, 2021 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Hycor Biomedical LLC
- Other trademarks owned by Hycor Biomedical LLC
- Other trademarks owned by Hycor Biomedical LLC
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 037
- Other trademarks in Class 042
- Similar marks named NOVEOS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 30, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Mar 30, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 20, 2021 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Feb 19, 2021 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Feb 9, 2021 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jan 28, 2021 | IUAF | USE AMENDMENT FILED | — |
| Jan 28, 2021 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Aug 19, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 18, 2020 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Aug 18, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Aug 5, 2020 | EXT5 | SOU EXTENSION 5 FILED | — |
| Aug 5, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 7, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 5, 2020 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Feb 5, 2020 | EXT4 | SOU EXTENSION 4 FILED | — |
| Feb 5, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 7, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 5, 2019 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Aug 5, 2019 | EXT3 | SOU EXTENSION 3 FILED | — |
| Aug 5, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 7, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 5, 2019 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 5, 2019 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 5, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 7, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 3, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 3, 2018 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 3, 2018 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 3, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 6, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 12, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 12, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 22, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 9, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 9, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 9, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 9, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 9, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 6, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 6, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 3, 2017 | ALIE | ASSIGNED TO LIE | — |
| Oct 23, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 11, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 11, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 11, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 8, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 15, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 12, 2017 | NWAP | NEW APPLICATION ENTERED | — |